摘要
三阴性乳腺癌(triple-negative breast cancer,TNBC)恶性程度高,易出现复发和转移,除手术和化疗外,目前缺乏有效的治疗手段。以免疫检查点抑制剂(immune checkpoint inhibitor,ICI)为主的免疫疗法的兴起为其治疗带来了曙光,但仍有一部分患者难以从中获益。最新研究提示,肠道微生物及其代谢产物可通过调节肿瘤免疫微环境(tumor immune microenvironment,TIME)影响TNBC的免疫疗效。文章就肠道微生物与TNBC免疫治疗关联的最近研究进展作一综述,以期为疾病的免疫治疗提供新思路。
Triple-negative breast cancer(TNBC)is highly malignant and prone to recurrence and metastasis,which currently lacks effective treatment except surgery and chemotherapy.The emergence of immunotherapy,mainly immune checkpoint inhibitor(ICI),has provided a new strategy for TNBC treatment.Nevertheless,some patient population still can not benefit from immunotherapy.Recent studies suggest that gut microbiota and their metabolites may influence the immune efficacy of ICI on TNBC by regulating the tumor immune microenvironment(TIME).This review discusses the recent progress on the connection between gut microbiota and TNBC immunotherapy,aiming to provide new ideas for immunotherapy of this disease.
作者
刘琴国
陈棋帅
马志军
LIU Qinguo;CHEN Qishuai;MA Zhijun(Graduate School,Qinghai University,Xining 810016,China;Department of Oncology Surgery,Qinghai University Affiliated Hospital,Xining 810012,China)
出处
《现代免疫学》
2025年第3期334-338,共5页
Current Immunology
基金
国家自然科学基金地区项目(82060485)。
关键词
肠道微生物
三阴性乳腺癌
免疫检查点抑制剂
肿瘤免疫微环境
gut microbiota
triple-negative breast cancer
immune checkpoint inhibitor
tumor immune microenvironment
